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year overall survival rate was 55.5%.
Conclusions: In our experience, ASCT was associated with
excellent disease control and outcomes in patients with











Number 76 12 40
Median age (range) 54 (16-72) 52 (22-72) 55 (26-70)
Conditioning
Regimen:
Melphalan 41 (54%) 5 (42%) 25 (62%)
Myeloablative
chemotherapy
35 (46%) 7 (58%) 15(38%)
Autologous Stem
Cell Source:
Peripheral blood 68 (89%) 12 (100%) 39 (98%)
Bone marrow 6 (8%) 0 0
Both 2 (3%) 0 1 (2%)
Bortezomib use:
Prior to transplant 10 (13%) 5 (42%) 15 (38%)
Post transplant 5 (7%) 0 5 (12%)152
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Busulfan (Bu) is commonly used with cyclophosphamide
(Cy) as a conditioning regimen for HPCT. We previously re-
ported that substituting IV for oral Bu was associated with
less relapses and superior relapse free (RFS) and overall
survivals (OS) for relapsed or refractory NHL pts undergoing
AHPCT (Br J Haematol 2010;148:226-34). It is unknown
whether such a beneﬁt exists for IV Buwhen usedwith Cy for
AHPCT for plasma cell myeloma.We performed a prospective
studywith this regimenwithout Bu dose adjustment in order
to compare outcomes with historical controls who received
oral Bu at our institution. 55 pts were transplantedwith IV Bu
from 7/29/09-8/23/12 and 117 oral Bu pts were transplanted
from 3/22/94-4/6/06. IV Bu pts were older (P < 0.001), more
often had lower Karnofsky PS at HPCT (P< 0.001), more prior
therapies (P < 0.001), more advanced disease status at HPCT
(p¼0.002) and a longer median time from diagnosis to HPCT
(14 vs 8 mos, P < 0.001). More oral Bu pts received G-CSF
alone for mobilization therapy (90 vs 46%, P < 0.001), had
more days of apheresis (median 3 vs 2, P< 0.001) and higher
median CD34+ and TNC doses (7.22 vs 4.68 x 106/kg,
respectively, P< 0.001; 12.60 vs. 8.52 x 108/kg, respectively, P
< 0.001). There were no differences in time to neutrophil
engraftment, but platelet engraftment was more rapid for
oral Bu pts (median 11 vs 15 d, P < 0.001). Oral Bu pts had
signiﬁcantly more and worse mucositis by the modiﬁed
OMAS (66% vs. 0%, P < 0.001; median scores 0.2 vs. 0, P <
0.001). IV Bu pts had more infections (p¼0.034), but there
were no differences between the groups regarding CMV
infection, GI or pulmonary toxicity, relapse, relapse free
survival RFS or OS. At this time 46 (84%) of the IV Bu and 39
(33%) of the oral Bu pts are alive, however, the median follow
up was longer for the oral Bu pts (118 vs 13 mos, P < 0.001).
The median RFS and OS have not yet been observed in the IV
Bu group, but were 26 and 63 months, respectively for the
oral Bu pts. Disease relapse was the most common cause of
death for both the IV and oral Bu pts (67% and 77% of deaths).
1 and 2 year relapse mortality rates were 7% and 19% for IV
Bu pts and 7% and 22% for oral Bu pts. 1 and 2 year non-
relapse mortality rates were 5% and 12% for IV Bu and 4% and
4% for oral Bu. Death due to pulmonary toxicity occurred in 4
oral Bu pts and 0 IV Bu pts. Based upon these preliminary
results using IV instead of oral Bu decreases toxicity and
potentially improves safety as suggested from our ﬁnding of
signiﬁcantly less oral mucositis and no pulmonary deaths
with IV Bu. Further follow up of the IV Bu pts is required to
adequately assess for a survival beneﬁt. Investigation of PK
based Bu dosing strategies in this transplant setting may be
appropriate to help elucidate whether outcomes may be
further improved.153
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Introduction: Varicella-Zoster Virus (VZV) infection is
a relatively common cause of morbidity following autologous
hematopoietic cell transplant (auto-HCT). Previous guide-
lines recommended antiviral prophylaxis against VZV only
during the post HCT neutropenia period. The CDC in 2009
recommended extending VZV prophylaxis for 1 year post-
transplantation.
Methods:We retrospectively analyzed rates of VZV infection
following auto-HCTat our transplant center prior to and after
the implementation of extended acyclovir prophylaxis in
June 2008. We divided our study population into three
different cohorts according to the length of VZV prophylaxis:
(1) prophylaxis until neutrophil recovery to 500/uL (n¼76),
(2) prophylaxis for 6months (n¼12) or (3) 12months (n¼40)
post auto-HCT. All patients received acyclovir 400 mg oral or
iv twice daily or valacyclovir 500 mg oral daily. For patients
in whom VZV infection occurred, data was collected on
severity of infection, timing of onset, treatment of the reac-
tivation and any associated complications.
Results: 128 patients undergoing auto-HCT between January
1,2004 and January 31, 2010were included in the study. Table
1 demonstrates baseline characteristics for the three cohorts.
By Fisher's exact test, there was a signiﬁcant difference in
rates of VZV infection between the neutrophil recovery and
12months prophylaxis cohorts at 14% (n¼11) and 2% (n¼1)
(P¼0.03), respectively. VZV infection rate in the 6months
prophylaxis groupwas 16% (n¼2), but did not reach statistical
signiﬁcance due to small numbers. Median time to the onset
of VZV infection was 4 months (1-10 months) in the neutro-
phil recovery group, whereas only 1 event occurred in the 12
month prophylaxis group at 19-months post-transplant.
Complications observed with VZV infections include post-
